398
Views
3
CrossRef citations to date
0
Altmetric
Reviews

The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems

Pages 2588-2591 | Received 12 Mar 2013, Accepted 12 Mar 2013, Published online: 07 May 2013
 

Abstract

In 1976 the French–American–British (FAB) Leukemia Working Group proposed the first definitions of patients with myelodysplastic syndromes (MDS), namely refractory anemia with excess blasts (RAEB) and chronic myelomonocytic leukemia (CMML). Subsequent publications resulted in additional subgroups that had prognostic significance. Incorporation of the subgroupings by the World Health Organization and additional fine tuning of the degrees of morphologic dysplasia and percentage of blasts have enhanced the classification. Several prognostic scoring systems have added degrees of cytopenia, cytogenetic aberrations and molecular genetic mutations that allow care providers to subdivide cases into lower, intermediate and higher grade categories.

Acknowledgements

My appreciation goes to the “FAB” members, Professor Nukhet Tuzuner and Drs. Jean Goasguen and Rami Komrokji for years of support and friendship, and to Ms. Phoebe Downing for valuable editorial support over the past two decades.

Potential conflict of interest

A disclosure form provided by the author is available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.